Objectives:

  1. Discuss the role of pharmacogenomics in the identification of opportunities to reduce chemotherapy related toxicities
  2. Provide examples of drug-gene interactions which allow translation of germline genomic findings into clinical oncologic practice

and

  1. Examine the role of tumor microenvironment adenosine in immune evasion.
  2. Improve understanding of the pre-clinical data for A2AAR antagonists currently in clinical trial.
  3. Integrate epidemiologic data into pre-clinical pathway evaluation for investigational drugs, using A2AAR-targeted compounds as a case example.
Session date: 
Monday, November 5, 2018 - 12:00pm to 1:00pm
Speaker Name: 
Natalie M. Reizine, MD and Garth W. Strohbehn, MD, MPhil
Location: 
UCMC
5841 South Maryland Avenue
MC2115 HemOncConference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.